Related Experiment Video
Updated: Mar 1, 2026

CD Spectroscopy to Study DNA-Protein Interactions
Published on: February 10, 2022
Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent
Christine E Kaiser1, Natalie A Van Ert1, Prashansa Agrawal1
1College of Pharmacy, University of Arizona , Tucson, Arizona 85721, United States.
Abstract:
Activating KRAS mutations frequently occur in pancreatic, colorectal, and lung adenocarcinomas. While many attempts have been made to target oncogenic KRAS, no clinically useful therapies currently exist. Most efforts to target KRAS have focused on inhibiting the mutant protein; a less explored approach involves targeting KRAS at the transcriptional level. The promoter element of the KRAS gene contains a GC-rich nuclease hypersensitive site with three potential DNA secondary structure-forming regions. These are referred to as the Near-, Mid-, and Far-regions, on the basis of their proximity to the transcription start site. As a result of transcription-induced negative superhelicity, these regions can open up to form unique DNA secondary structures: G-quadruplexes on the G-rich strand and i-motifs on the C-rich strand. While the G-quadruplexes have been well characterized, the i-motifs have not been investigated as thoroughly. Here we show that the i-motif that forms in the C-rich Mid-region is the most stable and exists in a dynamic equilibrium with a hybrid i-motif/hairpin species and an unfolded hairpin species. The transcription factor heterogeneous nuclear ribonucleoprotein K (hnRNP K) was found to bind selectively to the i-motif species and to positively modulate KRAS transcription. Additionally, we identified a benzophenanthridine alkaloid that dissipates the hairpin species and destabilizes the interaction of hnRNP K with the Mid-region i-motif. This same compound stabilizes the three existing KRAS G-quadruplexes. The combined effect of the compound on the Mid-region i-motif and the G-quadruplexes leads to downregulation of KRAS gene expression. This dual i-motif/G-quadruplex-interactive compound presents a new mechanism to modulate gene expression.
Insights
Researchers discovered a new way to target KRAS gene expression by stabilizing DNA structures. A compound was found to interact with both i-motif and G-quadruplex DNA, leading to KRAS gene downregulation.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Activating KRAS mutations are common in pancreatic, colorectal, and lung cancers.
- Targeting KRAS mutations has proven challenging, with no effective therapies currently available.
- Most therapeutic strategies focus on inhibiting mutant KRAS protein, neglecting transcriptional regulation.
Purpose of the Study:
- To explore targeting KRAS at the transcriptional level by investigating DNA secondary structures in its promoter region.
- To characterize the i-motif DNA secondary structures within the KRAS promoter.
- To identify compounds that modulate KRAS transcription via these DNA structures.
Main Methods:
- Analysis of DNA secondary structures (G-quadruplexes and i-motifs) in the KRAS promoter.
- Investigation of the interaction between transcription factor hnRNP K and KRAS i-motifs.
- Screening for compounds that affect i-motif and G-quadruplex stability and their interaction with hnRNP K.
Main Results:
- The C-rich Mid-region of the KRAS promoter forms a stable i-motif structure.
- The transcription factor hnRNP K binds selectively to the i-motif and enhances KRAS transcription.
- A benzophenanthridine alkaloid was identified that destabilizes the i-motif/hnRNP K interaction and stabilizes KRAS G-quadruplexes.
Conclusions:
- A novel dual-acting compound downregulates KRAS expression by targeting both i-motif and G-quadruplex structures in the KRAS promoter.
- This dual modulation of DNA secondary structures offers a new therapeutic strategy for KRAS-driven cancers.
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
RNA Polymerase II Accessory Proteins
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation

